Adverse effects [2 weeks to 6 months] · Children with otitis media with effusion
Summary of findings: oral steroids plus antibiotic showed no clear difference in adverse effects [2 weeks to 6 months] compared with control plus antibiotic (low certainty).
1 finding from 1 review
Hearing loss · Children with otitis media with effusion
Summary of findings: oral steroids plus antibiotic showed no clear difference in hearing loss [2 months]1 compared with control plus antibiotic (moderate certainty).
1 finding from 1 review
OME resolution at short‐term · Children with otitis media with effusion
Summary of findings: oral steroids plus antibiotic leads to higher OME resolution at short‐term compared with control plus antibiotic (high certainty).
1 finding from 1 review
OME resolution at intermediate‐term · Children with otitis media with effusion
1 finding from 1 review
Physician's assessment of global response of improvement, clear or excellent ‐ 6 weeks · people with atopic dermatitis
Tacrolimus 0.03% probably leads to higher physician's assessment of global response of improvement, clear or… compared with corticosteroids (moderate certainty).
4 findings from 1 review
RR 2.05 [1.36, 3.08]
1 study · 411 participants
Moderate
RR 2.58 [1.96, 3.38]
2 studies · 790 participants
Moderate
RR 0.45 [0.13, 1.57]
2 studies · 409 participants
Very low
Show 1 more finding
Adverse effects ‐ burning · people with atopic dermatitis
1 finding from 1 review
Hearing loss · Children with otitis media with effusion
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
OME resolution at short‐term · Children with otitis media with effusion
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
OME resolution at intermediate‐term · Children with otitis media with effusion
Summary of findings: intranasal steroids plus oral antibiotic showed no clear difference in OME resolution at intermediate‐term compared with control plus antibiotic (moderate certainty).
1 finding from 1 review
OME resolution at long‐term · Children with otitis media with effusion
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptom score [3 months] · Children with otitis media with effusion
1 finding from 1 review
no estimate extracted
39 participants
Moderate
Adverse effects [3 months] · Children with otitis media with effusion
1 finding from 1 review
Number of participants achieving 'clearance' by IGA · scalp psoriasis
Steroid plus vitamin D leads to higher number of participants achieving 'clearance' by IGA compared with vitamin D (high certainty).
1 finding from 1 review
Number of participants achieving 'response' by IGA · scalp psoriasis
Steroid plus vitamin D probably leads to higher number of participants achieving 'response' by IGA compared with vitamin D (moderate certainty).
1 finding from 1 review
Quality of life · scalp psoriasis
1 finding from 1 review
Number of participants withdrawing due to adverse events (AE) · scalp psoriasis
Steroid plus vitamin D leads to lower number of participants withdrawing due to adverse events compared with vitamin D (high certainty).
1 finding from 1 review
Number of participants achieving 'response' by PGA · scalp psoriasis
Steroid plus vitamin D probably leads to higher number of participants achieving 'response' by PGA compared with vitamin D (moderate certainty).
1 finding from 1 review
Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time within 1‐5 weeks) · children and adults with mild to severe eczema
Moderate‐potency probably leads to higher clinician‐reported signs of eczema: IGA (number with cleared or… compared with mild‐potency topical corticosteroid (moderate certainty).
1 finding from 1 review
Patient‐reported symptoms of eczema · children and adults, most with moderate to severe eczema
Potent may leads to lower patient‐reported symptoms of eczema: PGA; short‐term (week 1) compared with moderate‐potency topical corticosteroid (low certainty).
1 finding from 1 review
Local adverse events: skin thinning; end of treatment (1 to 3 weeks) · children and adults, most with moderate to severe eczema
1 finding from 1 review